RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.

Romain CohenJaafar BennounaAurélia MeurisseChristophe TournigandChristelle De La FouchardièreDavid TougeronChristophe BorgThibault MazardBenoist ChibaudelMarie-Line Garcia-LarnicolMagali SvrcekDewi VernereyYves MenuThierry André

Published in: Journal for immunotherapy of cancer (2021)

NCT03350126.

Keyphrases

phase ii study
metastatic colorectal cancer
open label
locally advanced
placebo controlled
rectal cancer
clinical trial
squamous cell carcinoma
randomized controlled trial
genetic diversity
radiation therapy
study protocol
wild type
double blind